Silver Book Fact

Drug-resistant MRSA expensive to treat

As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.

Mauldin, Patrick D., Cassandra D. Salgado, Ida Solhoj Hansen, Darshana T. Durup, and John A. Bosso. Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria. Antimicrob Agents Chemother. 2009; 54(1): 109-15. http://aac.asm.org/content/54/1/109.full

Reference

Title
Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria
Publication
Antimicrob Agents Chemother
Publication Date
2009
Authors
Mauldin, Patrick D., Cassandra D. Salgado, Ida Solhoj Hansen, Darshana T. Durup, and John A. Bosso
Volume & Issue
Volume 54, Issue 1
Pages
109-15
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • HAIs cost patients additional $43,000 per hospital stay
    Patients with HAIs cost, on average, $43,000 more per hospital stay than those without an infection ($52,096 vs. $9,377).  
  • 1 in 10 HAI hospital stays from sepsis
    1 in 10 hospital stays with HAIs have a principal diagnosis of septicemia.  
  • Risk of HAIs from hospitalization increases with age
    Hospitalized elderly patients are 2 – 5 times more likely to develop a healthcare-associated infection than younger patients.  
  • Patients hospitalized for sepsis experience poor outcomes
    Compared with patients hospitalized with other diagnoses, patients hospitalized for sepsis/septicemia are: 1/2 as likely to be discharged home 2 times more likely to be discharged to other short-term care 3 times more…  
  • Antibiotic resistance of Klebsiella pneumoniae on the rise
    Resistance of Klebsiella pneumoniae to antibiotics has dramatically increased- from 5.3% to 11.6% for third generation cephalosporins (between 1999 and 2010), and from <0.1% to 4.5% for carbapenams (between 2002…